Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

This trial is divided into four distinct periods: 1. Baseline Period during which each patient is taken off pancreatic enzyme medications. 2. An Open-Label Treatment Period during which all patients will receive ALTU-135 (liprotamase). 3. Inpatient, Double Blind Treatment Period during which half of patients will be withdrawn from treatment and will receive Placebo. 4. Second Open-Label Treatment Period during which all patients will resume treatment with ALTU-135 (liprotamase).